Revelation Biosciences
REVB
3 hedge funds and large institutions have $20.9K invested in Revelation Biosciences in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 5 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
40% less funds holding
Funds holding: 5 → 3 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
96% less capital invested
Capital invested by funds: $467K → $20.9K (-$447K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$26.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$19.3K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$207K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$202K |
| 3 |
Axa
Paris,
France
|
-$27.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$17.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.1K |
REVB Hedge Fund Activity: Q1 2024 in Review
3 of the 6,951 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q1 2024, worth a combined $20.9K — down 96% from $467K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of REVB and 3 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $26.5K. The largest seller was Walleye Capital, exiting entirely with an estimated $207K sold.
- 3 institutional investors held Revelation Biosciences (REVB) as of Q1 2024, down from 5 in Q4 2023.
- Funds reported $20.9K of Revelation Biosciences stock for Q1 2024, down 96% quarter-over-quarter.
- 3 funds opened new Revelation Biosciences positions in Q1 2024 and 5 closed out, a net change of -2 holders.
- The largest Revelation Biosciences buyer in Q1 2024 was UBS Group, an estimated $26.5K added.
- The largest Revelation Biosciences seller in Q1 2024 was Walleye Capital, an estimated $207K sold.
Based on aggregated 13F filings for Q1 2024.